Rationale: Vemurafenib, an inhibitor of mutated B-rapidly accelerated fibrosarcoma, is frequently used in the treatment of melanoma and Erdheim-Chester disease (ECD) patients. Inflammatory adverse effects have been increasingly reported after vemurafenib treatment.
Introduction
Vemurafenib (PLX4032) is an inhibitor of mutated B-rapidly accelerated fibrosarcoma (BRAF), especially BRAF V600E . [1] Metastatic melanoma patients treated with vemurafenib showed a response rate of 48% and improved survival. [2] Erdheim--Chester disease (ECD) is a rare non-Langherans cell hystiocytosis where BRAF V600E mutation is frequently found. [3, 4] ECD patients with BRAF V600E presented good response when treated with vemurafenib. [5, 6] Serious adverse effects (SAEs) were reported in 8% of patients treated with vemurafenib for metastatic melanoma. [2] SAEs were also reported in 94% of ECD or Langherans cell histocytiosis patients treated with vemurafenib. [6] Main side effects included skin (rash, squamous cell carcinoma, hyperkeratosis, alopecia) and gut involvement (nausea, diarrhea), cytopenia, and arthralgia. [2] More recently, inflammatory adverse effects like panniculitis have been reported. [7] Very few cases of vemurafenibassociated vasculitis have been reported. [8] [9] [10] Vasculitis may be life-threatening depending on which organ is involved.
Herein, we report a patient with ECD with vemurafenibassociated severe systemic vasculitis. We reviewed the literature and analyzed 5 additional cases of vemurafenib-associated vasculitis.
Methods
The patient reported was followed in Internal Medicine and Clinical Immunology Department at Pitié-Salpêtrière University Hospital, Paris, France. Demographic, medical history, laboratory, imaging, histology, treatment, and follow-up data were extracted from medical records. Patient gave his informed consent.
Literature review
MEDLINE (National Library of Medicine, Bethesda, MD) search was performed until April 2016 using [vemurafenib] or [BRAF inhibitor] and [vasculitis] . Five cases were identified and analyzed.
Patient
We report a 75-year-old man with a 7-year history of ECD admitted in our department. He had a past medical history with arterial hypertension, type 2 diabetes, ST-elevation myocardial infarction (STEMI) without chronic heart failure, and nonalcoholic steatohepatitis. ECD was diagnosed in 2009 on a biopsy sample of perirenal fibrosis, showing foamy CD68 + CD1aÀ histiocytes. Immunohistochemistry analysis detected the presence of BRAF V600E mutation. Thoracoabdominal computed tomography (CT) scan showed a right pleural effusion, mesenteric panniculitis, right upper femoral metaphysis osteosclerosis, and perirenal fibrosis with hairy kidney sign. Brain magnetic resonance imaging (MRI) showed a left retro-orbital mass. Pegylated interferon a (PEG-IFN) treatment was started in October 2009. Because of disease progression, PEG-IFN was stopped in September 2010 and a recombinant human interleukin (IL)-1 receptor antagonist treatment was initiated. This treatment permitted disease control, but was stopped in September 2013 because of skin adverse effects. Our patient was treated with infliximab from September 2013 to January 2014. This treatment was stopped due to disease progression. A targeted therapy with BRAF V600E inhibitor (vemurafenib) was initiated in January 2014 at 480 mg/d. In September 2014, the dose was reduced to 240 mg/d because of cholestasis. In February 2015, the treatment dose was resumed to 480 mg. This treatment permitted disease control. In February 2016, our patient was admitted to our department for annual disease re-evaluation. Clinical evaluation showed leg edema, infiltrated purpura on the legs, and bilateral lung crackles. Biological explorations found acute kidney injury with serum creatinine level of 225 mmol/l and C-reactive protein (CRP) was elevated at 16 mg/l. Kidney ultrasound showed no renal dilatation. Urine sediment analysis showed microscopic hematuria (47. 10 4 red blood cells/ml). Urine biological explorations found a glomerular proteinuria, with urine protein-to-creatinine ratio of 0.25 g/mmol and albumin-tocreatinine ratio of 0.2 g/mmol. Immune explorations found no complement consumption, no antineutrophil cytoplasmic antibody (ANCA), no cryoglobulins and rheumatoid factor, and no anti-glomerular basement membrane antibody (anti-GBM). Antinuclear antibodies (ANAs) were positive at a 1:320 dilution, with no anti-DNA (ELISA) and no anti-extractable nuclear antigen (ENA). Kidney function worsened in few days to a serum creatinine level of 410 mmol/l. Kidney biopsy sample analysis showed 13 glomeruli with normal permeability (Fig. 1) . One glomerulus presented a crescent, compatible with extracapillary proliferative glomerulonephritis. Immufluorescent analysis showed pauci-immune glomerulonephritis (ie, no immunoglobulin deposit, no C1q deposit, no light chains deposit, and some C3 deposits). Thoracoabdominal CT scan and brain MRI findings showed no signs of ECD evolution. We retained the diagnosis of vemurafenib-associated vasculitis with skin and kidney involvement. Vemurafenib was stopped. Our patient was treated with high-dose glucocorticosteroids (methyprednisolone pulse of 1 g/d during 3 days) and cyclophosphamide (0.5 g/m 2 ), monthly during 2 months. Glucocorticosteroids were pursued with prednisone orally at 1 mg/kg/d. The outcome was favorable with quick renal function improvement (Fig. 1). 
Literature review
To our knowledge, there are only 5 additional reported cases of vemurafenib-associated vasculitis (Table 1) . [8] [9] [10] [11] Apart from our patient, all 5 other patients received vemurafenib as treatment for metastatic melanoma. Median age was 47 (29.8; 58.5) years and sex ratio was 1. Vasculitis appeared 15.5 (9.5; 232.8) days after treatment initiation. Three patients (60%) described arthralgia associated with skin vasculitis. All patients presented biological inflammatory syndrome with elevated CRP. Elevated ANA titers were detected in 3 cases. Vasculitis was biopsy-proven in every case. Vemurafenib treatment was stopped in 3 cases, continued with reduced doses in 1 case, and continued at the same dose in 2 cases (Table 2) . Three patients (60%) received steroids as vasculitis treatment. In 1 case, vasculitis relapsed after vemurafenib therapy was restarted. No progressive neoplasm was reported after vasculitis treatment.
Discussion
Since BRAF inhibitors have entered the field of neoplasm therapy, inflammatory adverse effects have been increasingly reported. [9] [10] [11] [12] [13] [14] [15] These adverse effects were mainly skin reactions like panniculitis. Skin vasculitis has already been described in 5 patients treated with vemurafenib. [8] [9] [10] [11] Severe systemic vasculitis, including rapidly progressive kidney glomerulonephritis, has never been described to our knowledge.
Other vasculitis-reported cases involved mainly skin and joints. In these cases, vasculitis appeared early after vemurafenib treatment initiation, within the first month. In 1 case, vasculitis appeared 11 weeks after treatment initiation. [8] In our case, serum creatinine level began to increase 20 months after vemurafenib treatment initiation. A delay of more than 1 year We observed a dramatic improvement within days after corticosteroid therapy combined with cyclophosphamide. CSB = corticosteroids bolus, CYC = cyclophosphamide.
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Medicine of BRAF inhibitor treatment has already been described in a patient who developed panniculitis. [8] Acute kidney injury has already been described during vemurafenib treatment. [16] However, the diagnosis was an acute immunoallergic interstitial nephritis and there was no evidence of vasculitis.
Vemurafenib-associated vasculitis seems to be very rare. Thus, there is no consensus for vasculitis management. For some reported patients, vasculitis regressed only with vemurafenib dose reduction. For other patients, a treatment with steroids has been necessary. In patients treated with vemurafenib for metastatic melanoma, vemurafenib could be continued or restarted after vasculitis management. This is very important for neoplasm control and patient survival. However, restarting vemurafenib treatment may induce vasculitis relapse. [8] In our case, vemurafenib has been stopped because kidney vasculitis might induce kidney failure and require extrarenal replacement therapy. For our patient, vemurafenib benefit might not be superior to the risk of kidney failure.
The pathogenesis of BRAF inhibitor associated vasculitis is not clear. It has been shown that RAF inhibitors inhibit extracellular signal-regulated kinase (ERK) signaling in cells with mutant BRAF, but unexpectedly enhance signaling in cells with wild-type BRAF. [17] It explains why incidence of some neoplasms, like cutaneous squamous cell carcinomas, is more important in vemurafenib-treated patients. Furthermore, it has been shown that stimulation of neutrophils with lipopolysaccharide (LPS) resulted in the activation of ERK and p38 mitogen-activated protein kinase (MAPK). [18] MAPK pathway activation was associated with neutrophil migration and may explain inflammatory reactions.
It could be hypothesized that BRAF V600E inhibitors like vemurafenib could paradoxically activate BRAF wild-type and RAS (RAt Sarcoma) pathway in other cells and induce vasculitis or other inflammatory reactions.
In conclusion, inflammatory disorders associated with BRAF inhibitors are increasingly reported. Vasculitis is a rare vemurafenib-induced adverse event that may be life-threatening. Kidney involvement might lead to kidney failure. Continuing or restarting vemurafenib therapy may induce vasculitis relapse. [8] Discontinuation
Yes 24 None Relapse Yes CR 3 [8] No
No NA None Remission NA PR 4 [10] Dose reduction No NA None Remission NA ND 5 [9] Discontinuation Yes 60 None Remission Yes PR 6 [11] No No NA None Remission NA ND CR = complete remission, CYC = cyclophosphamide, IS = immunosuppressant, NA = not applicable, ND = not documented, PR = partial remission, SD = stable disease.
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